{"filing":{"accession_number":"0001193125-26-296936","cik":"0001833214","ticker":"SABSW","company_name":"SAB Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"sabs-20260707.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526296936/sabs-20260707.htm"},"events":[{"id":16324,"run_id":14575,"accession_number":"0001193125-26-296936","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study evaluating SAB-142 in Stage 3 Type 1 Diabetes patients. This represents a material operational and clinical development milestone—the expansion of the company's clinical program into a new patient population (100 days to 2 years post-diagnosis) with external funding support. While the disclosure is operational in nature (a clinical trial advancement), it does not fit neatly into the specific operational categories (no material contract, partnership, or regulatory milestone language), making operational_other the most appropriate classification.","company_name":"SAB Biotherapeutics, Inc.","ticker":"SABSW","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14392,"accession_number":"0001193125-26-296936","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study evaluating SAB-142 in Stage 3 Type 1 Diabetes patients. This represents a material operational and clinical development milestone—the expansion of the company's clinical program into a new patient population (100 days to 2 years post-diagnosis) with external funding support. While the disclosure is operational in nature (a clinical trial advancement), it does not fit neatly into the specific operational categories (no material contract, partnership, or regulatory milestone language), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:14:04.412127+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14392,"accession_number":"0001193125-26-296936","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study evaluating SAB-142 in Stage 3 Type 1 Diabetes patients. This represents a material operational and clinical development milestone—the expansion of the company's clinical program into a new patient population (100 days to 2 years post-diagnosis) with external funding support. While the disclosure is operational in nature (a clinical trial advancement), it does not fit neatly into the specific operational categories (no material contract, partnership, or regulatory milestone language), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:14:04.412127+00:00","company_name":"SAB Biotherapeutics, Inc.","ticker":"SABSW","filing_date":"2026-07-07"}]}